Abstract | INTRODUCTION: AREAS COVERED: The authors reviewed preclinical and clinical data examining the safety of vemurafenib in melanoma. MEDLINE and EMBASE were searched using the medical subject heading ' vemurafenib' and the following text terms: melanoma, BRAF inhibition, vemurafenib. This review provides the reader with an overview of current data examining the efficacy and safety of vemurafenib in metastatic melanoma. EXPERT OPINION:
|
Authors | Emmet John Jordan, Catherine M Kelly |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 13
Issue 17
Pg. 2533-43
(Dec 2012)
ISSN: 1744-7666 [Electronic] England |
PMID | 23094782
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Indoles
- Protein Kinase Inhibitors
- Sulfonamides
- Vemurafenib
- BRAF protein, human
- Proto-Oncogene Proteins B-raf
|
Topics |
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Drug Resistance, Neoplasm
- Humans
- Indoles
(pharmacology, therapeutic use)
- Melanoma
(drug therapy)
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Proto-Oncogene Proteins B-raf
(antagonists & inhibitors, genetics)
- Sulfonamides
(pharmacology, therapeutic use)
- Vemurafenib
|